It’s important for a company to have a strong advisory board to help guide them toward the right path. $AGN.C just appointed Dr. Peter Dicpinigaitis to the board, and he certainly has the qualifications to back him up.
- He is a faculty member of the Division of Critical Care Medicine at Montefiore Medical Center
- Is the founder and director of the Montefiore Cough Center, a specialty centers committed to the evaluation and management of patients with chronic coughs.
- Has authored/co-authored numerous journals and guidelines over his 25 years of experience in the space.
Due to his expertise around cough, without a doubt, he’ll be a key player for the company’s success moving into 2023 as they continue to undergo trials for their repurposed drug program.
https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-appoints-dr-peter-120000953.html
Beyond this, $AGN.C has been working hard in developing their flagship treatments with the recently announced 180-patient, 90-day Phase 2b study of Ifenprodil for chronic cough in Q3 (https://themarketherald.ca/algernon-pharmaceuticals-announces-plans-for-a-180-patient-phase-2b-chronic-cough-study-of-ifenprodil-2023-01-09/). And with significant IP/market potential backing $AGN.C from their use of DMT on stroke victims to Ifenprodil on chronic cough (which has received an orphan designation from the FDA), the current $5.3M valuation provides significant upside potential, especially when considering the promising results from the previous studies. Definitely keep an eye out as they continue their trials and get closer to full approval.